CJC-1295 DAC Dosage Chart: Research Dosing Reference

There is no official CJC-1295 DAC dosage chart, but the most widely cited research protocol is 1 to 2 mg per week, given as one injection or split into two. The Drug Affinity Complex (DAC) extends the peptide's half-life to roughly six to eight days, which is why weekly dosing is standard rather than daily. CJC-1295 DAC is not FDA-approved for human use in the United States and is sold only as a laboratory research chemical.

What CJC-1295 DAC Is

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Instead of supplying growth hormone directly, it binds to GHRH receptors and prompts the pituitary to release the body's own GH.

The "DAC" portion is a Drug Affinity Complex, a maleimide linker that attaches to albumin in the bloodstream. Albumin binding slows clearance dramatically and stretches the half-life from minutes to days.

Because the compound stays active far longer than unmodified GHRH, total weekly exposure matters more than any single injection. Research discussions usually focus on IGF-1 levels measured over weeks rather than on short-term pulses.

CJC-1295 DAC Dosage Chart

The ranges below appear most often in published research summaries and vendor documentation. They are reference points for laboratory study, not medical guidance.

Protocol	Typical research dose	Frequency	Notes
CJC-1295 DAC (standard)	1–2 mg per week	1–2 injections per week	Most frequently cited range
CJC-1295 DAC (conservative start)	0.5–1 mg per week	Once weekly	Common titration approach
CJC-1295 DAC (higher end)	2 mg per week	Split into 2 x 1 mg	Reported in early clinical work
CJC-1295 No DAC	100–200 mcg per dose	2–3 times daily	Half-life of about 30 minutes
CJC-1295 No DAC + ipamorelin blend	100–300 mcg per dose	2–3 times daily	Vendor ratios vary widely

Note the units. DAC protocols are measured in milligrams, while the short-acting version is measured in micrograms. Confusing the two is the most common error found in self-reported logs.

How CJC-1295 DAC Compares With the No-DAC Version

These are two different molecules with different dosing schedules, even though both are sold under the CJC-1295 name. A cjc-1295 no dac dosage chart will look nothing like the table above, because the short form peaks and clears within roughly half an hour.

Feature	CJC-1295 DAC	CJC-1295 No DAC
Half-life	About 6–8 days	About 30 minutes
Typical dose range	1–2 mg per week	100–200 mcg per dose
Injection frequency	1–2 times per week	2–3 times per day
Units used	Milligrams	Micrograms
Albumin binding	Yes (the DAC group)	No
Common pairing	Rarely blended	Often blended with ipamorelin

In short, CJC-1295 DAC is dosed in milligrams once or twice a week, and CJC-1295 no DAC is dosed in micrograms two to three times a day.

Weekly Dosing and Injection Timing

Many published summaries of cjc-1295 with dac dosage settle on 1 to 2 mg per week, administered as a single injection or split into two doses spaced three to four days apart.

Timing relative to meals and sleep is debated. Some protocols call for dosing before bed to align with the body's natural nighttime GH pulse, while others treat timing as largely irrelevant given the long half-life.

Community reports tell a similar story. Threads you find searching cjc 1295 dac dosage per week reddit often describe 1 to 2 mg weekly, though many self-reported logs also mention starting lower and adjusting based on side effects such as flushing, headache, or injection-site irritation.

Anecdotes from forums are not data. Reddit posts are unverified, and self-reported dosing rarely includes bloodwork, product purity testing, or a control group.

Blends, Stacks, and Related Protocols

CJC-1295 is frequently discussed alongside ipamorelin, a selective ghrelin receptor agonist that triggers GH release through a different pathway. A cjc-1295 no dac ipamorelin 10mg blend dosage is usually described as 100 to 300 mcg of the mixed solution per injection, taken two or three times daily.

Because cjc-1295 no dac dosage is so much smaller and more frequent, the short-acting form is the one most often combined with ipamorelin in a single vial. Blend ratios vary by vendor, and a "10 mg blend" can mean 5 mg/5 mg or an entirely different split.

Stacking the DAC version with ipamorelin is less common. If someone does combine them, the CJC-1295 DAC portion is still dosed weekly while the ipamorelin portion is dosed daily, which makes a fixed-ratio blend impractical.

Safety and Legal Status

CJC-1295 DAC is not approved by the FDA for human use, and no prescribing guideline, standard dose, or safety database exists for it. Every chart labeled a CJC-1295 dosage guide is derived from animal studies, early clinical research from the 2000s, or community trial and error.

Reported effects in research settings have included injection-site reactions, flushing, headache, and changes in blood sugar regulation. Long-term effects on the pituitary and on IGF-1 levels are not well characterized.

• Buy only from vendors that publish third-party certificates of analysis.
• Understand that a "research chemical" label means the product is not intended for human consumption.
• Check sport anti-doping rules, because CJC-1295 is on the WADA prohibited list.
• Talk to a licensed healthcare professional before considering any use in humans.

Key Takeaways

• The most cited CJC-1295 DAC dose is 1 to 2 mg per week, given once or split into two injections.
• CJC-1295 DAC has a half-life of roughly six to eight days, while the no-DAC version clears in about 30 minutes.
• CJC-1295 no DAC is dosed in micrograms two to three times daily, not in milligrams per week.
• CJC-1295 DAC is not FDA-approved for human use in the United States.
• Forum anecdotes about weekly dosing are not a substitute for clinical evidence or medical supervision.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical CJC-1295 DAC dosage per week?

Most research references list 1 to 2 mg per week, given as one injection or split into two doses because of the peptide's long half-life of roughly six to eight days. There is no FDA-approved human dose for CJC-1295 DAC. Any human use is unapproved and carries unknown risks.

Is CJC-1295 DAC the same as CJC-1295 no DAC?

No. CJC-1295 DAC carries an albumin-binding group that extends its half-life to about six to eight days, so it is dosed in milligrams once or twice a week. The no-DAC version clears in about 30 minutes and is dosed in micrograms two to three times daily.

Is CJC-1295 DAC legal in the US?

CJC-1295 DAC is not FDA-approved for human use and is sold as a research chemical intended for laboratory study only. It also appears on the WADA prohibited list for athletes. Importing it for personal use may violate state or federal rules, so check your local regulations.